



June 13, 2021

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Re: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Subject: U.S. FDA issues Warning Letter for the Company's Somerset, New Jersey (USA) facility**

We wish to inform you that the Company has received a warning letter from the U.S. FDA for the Company's Somerset, New Jersey facility. The U.S. FDA had inspected the Lupin Somerset site from September 10, 2020 to November 5, 2020.

The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

We are committed to addressing the concerns raised by the U.S. FDA and will work with the FDA and the New Jersey District to resolve these issues at the earliest. We uphold quality and compliance issues with utmost importance and are committed to be compliant with Good Manufacturing Practice standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**